These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30712391)

  • 21. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
    Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
    J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.
    Morga A; Zimmermann L; Valluri U; Siddiqui E; McLeod L; Bender RH
    Adv Ther; 2024 Jul; 41(7):2845-2858. PubMed ID: 38775925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
    Rowan JP; Simon JA; Speroff L; Ellman H
    Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women.
    Rozenbaum H; Chevallier O; Moyal M; Durand G; Perineau M; This P;
    Climacteric; 2002 Sep; 5(3):249-58. PubMed ID: 12419083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
    Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
    Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
    Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
    Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial.
    Ivgy-May N; Roth T; Ruwe F; Walsh J
    Sleep Med; 2015 Jul; 16(7):831-7. PubMed ID: 26047890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
    Joffe H; Guthrie KA; Larson J; Cohen LS; Carpenter JS; Lacroix AZ; Freeman EW
    Menopause; 2013 Mar; 20(3):261-8. PubMed ID: 23435022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial.
    Ivgy-May N; Ruwe F; Krystal A; Roth T
    Sleep Med; 2015 Jul; 16(7):838-44. PubMed ID: 26047892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimation of placebo effect in randomized placebo-controlled trials for moderate or severe vasomotor symptoms: a meta-analysis.
    Zhou T
    Menopause; 2023 Jan; 30(1):5-10. PubMed ID: 36576440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.
    Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C
    Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
    Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
    Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women.
    Andrikoula M; Baker D; Nesic J; Liao LM; Duka T; Prelevic GM
    Climacteric; 2011 Oct; 14(5):544-50. PubMed ID: 21413865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
    Simon JA; Anderson RA; Ballantyne E; Bolognese J; Caetano C; Joffe H; Kerr M; Panay N; Seitz C; Seymore S; Trower M; Zuurman L; Pawsey S
    Menopause; 2023 Mar; 30(3):239-246. PubMed ID: 36720081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.